Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Axel Hauschild(University Hospital Schleswig-Holstein), David Gyorki(The University of Melbourne), John M. Kirkwood(UPMC Hillman Cancer Center), Bart A. van de Wiel(The Netherlands Cancer Institute), Ryan J. Sullivan(Dana-Farber Cancer Institute), Genevieve M. Boland(Harvard University), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Jane L. Messina(Moffitt Cancer Center), Elisa A. Rozeman(The Netherlands Cancer Institute), Miles C. Andrews(Alfred Health), Adil Daud(University of California, San Francisco), Alexander M. Menzies(The University of Sydney), Keith T. Flaherty(Cancer Research Center), Leslie A. Fecher(University of Pennsylvania), Keith A. Delman(Emory University), Roland L. Bassett(The University of Texas MD Anderson Cancer Center), Omid Hamid(Cedars-Sinai Medical Center), Diwakar Davar(University of Pittsburgh), Angela Hong(The University of Sydney), John F. Thompson(Melanoma Institute Australia), Janis M. Taube(Bloomberg (United States)), Elizabeth M. Burton(The University of Texas MD Anderson Cancer Center), Serigne Lo(The University of Sydney), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Tanja D. de Gruijl(Dutch Cancer Society), Kathryn Bollin(The Netherlands Cancer Institute), Alberto Fusi(Charité - Universitätsmedizin Berlin), Vernon K. Sondak(Advanced Dermatology), Brett Carter(RMIT University), Michael D. Farwell(University of Pennsylvania), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Helen Rizos(Macquarie University), Donald A. Berry(Berry & Associates (United States)), David E. Fisher(Massachusetts General Hospital), Jonathan Cohen(King's College London), Robert Antdbacka, Mark B. Faries(Angeles Clinic and Research Institute), Robyn P.M. Saw(Melanoma Institute Australia), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Matteo S. Carlino(The University of Sydney), Richard A. Scolyer(The University of Sydney), Kim Margolin(City Of Hope National Medical Center), Richard D. Carvajal(Northwell Health), Reinhard Dummer(University Hospital of Zurich), Matthew S. Block(Mayo Clinic in Arizona), Isabella C. Glitza(The University of Texas MD Anderson Cancer Center), Charlotte E. Ariyan(Memorial Sloan Kettering Cancer Center)
Cited by 219
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k